Table 5 |
||||||||||||
|
In-hospital outcomes for the three main bacterial pathogens, by study |
||||||||||||
|
Reference |
Bacteria |
Country |
No. of CBM cases |
In-hospital CFR |
Total no. cases assessed for sequelae |
HL (%) |
VL (%) |
CD (%) |
BP (%) |
MI (%) |
SZ (%) |
Any neuropsychological sequelae (%) |
|
|
||||||||||||
|
[38] |
Spn |
Cameroon |
74 |
39% |
45 |
16% |
||||||
|
[37] |
Spn |
Cote d'Ivoire |
330 |
60% |
132 |
25% |
||||||
|
[47] |
Spn |
Ghana |
33 |
36% |
||||||||
|
[67] |
Spn |
Mali and Niger |
115 |
67% |
38 |
21% |
||||||
|
[22] |
Spn |
The Gambia |
134 |
48% |
||||||||
|
[57] |
Spn |
Madagascar |
40 |
40% |
||||||||
|
[51] |
Spn |
Malawi |
62 |
44% |
32 |
25% |
||||||
|
[44] |
Spn |
Gabon |
42 |
29% |
30 |
20% |
||||||
|
[33] |
Spn |
Morocco |
141 |
9% |
128 |
27% |
||||||
|
[15] |
Spn |
Tunisia |
73 |
14% |
61 |
7% |
2% |
5% |
3% |
34% |
||
|
[41] |
Spn |
Egypt |
106 |
27% |
||||||||
|
[14] |
Spn |
South Africa |
79 |
30% |
55 |
5% |
38% |
|||||
|
[54] |
Spn |
Kenya |
92 |
36% |
59 |
32% |
||||||
|
[40] |
Spn |
Senegal |
142 |
32% |
96 |
28% |
||||||
|
[54] |
Hib |
Kenya |
77 |
17% |
64 |
25% |
||||||
|
[60] |
Hib |
Sudan |
25 |
16% |
||||||||
|
[38] |
Hib |
Cameroon |
53 |
25% |
40 |
15% |
||||||
|
[37] |
Hib |
Cote d'Ivoire |
314 |
21% |
248 |
6% |
1% |
2% |
17% |
|||
|
[36] |
Hib |
The Gambia |
77 |
25% |
||||||||
|
[67] |
Hib |
Mali and Niger |
133 |
36% |
85 |
28% |
||||||
|
[40] |
Hib |
Senegal |
216 |
18% |
178 |
6% |
3% |
2% |
27% |
|||
|
[22] |
Hib |
The Gambia |
123 |
27% |
||||||||
|
[66] |
Hib |
Burkina Faso |
92 |
22% |
72 |
7% |
18% |
|||||
|
[57] |
Hib |
Madagascar |
35 |
29% |
25 |
44% |
||||||
|
[51] |
Hib |
Malawi |
44 |
41% |
||||||||
|
[44] |
Hib |
Gabon |
36 |
31% |
||||||||
|
[59] |
Hib |
Algeria |
57 |
4% |
55 |
2% |
2% |
4% |
||||
|
[41] |
Hib |
Egypt |
56 |
30% |
||||||||
|
[42] |
Hib |
South Africa |
35 |
11% |
31 |
26% |
32% |
32%a |
||||
|
[45] |
Nm |
Ethiopia |
124 |
2% |
121 |
3% |
8% |
|||||
|
[62] |
Nm |
Sudan |
108 |
4% |
104 |
3% |
2% |
5% |
||||
|
[64] |
Nm |
Cameroon |
77 |
5% |
73 |
1%b |
1% |
3% |
||||
|
[67] |
Nm |
Mali and Niger |
161 |
13% |
140 |
5% |
||||||
|
[40] |
Nm |
Senegal |
153 |
5% |
146 |
10% |
||||||
|
[41] |
Nm |
Egypt |
267 |
6% |
||||||||
|
[34] |
Nm |
Morocco |
118 |
1% |
117 |
9% |
3% |
1% |
2% |
1% |
21% |
|
|
[50] |
Nm |
Tunisia |
57 |
4% |
||||||||
|
|
||||||||||||
|
This table presents the in-hospital sequelae and case fatality ratio (CFR) data available for 25 or more children diagnosed or surviving meningitis caused by 1 of the 3 main bacterial causes. Sequelae prevalences ranged from 16% to 38% for Spn meningitis, 4% to 44% for Hib meningitis and 3% to 21% for Nm meningitis. aEstimated 'Any neuropsychological sequelae' based on single sequelae type with largest proportion; bparalysis. BP = behavioural problem; CBM, confirmed bacterial meningitis; CD = cognitive delay; Hib = Haemophilus influenzae type b; HL = hearing loss; MI = motor impairment; Nm = Neisseria meningitidis; Spn = Streptococcus pneumoniae; SZ = seizures; VL = vision loss. |
||||||||||||
|
Ramakrishnan et al. BMC Medicine 2009 7:47 doi:10.1186/1741-7015-7-47 |
||||||||||||
